Description
1 × Kit (10 × 5 mg vials)
Semaglutide is a synthetic peptide analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It has been extensively studied in pre-clinical and clinical research settings for its role in metabolic regulation, glucose homeostasis, and appetite signalling pathways. Semaglutide is recognised for its long biological half-life and strong receptor selectivity within GLP-1 signalling systems.
Key Research-Backed Benefits
• Studied for its role in modulating appetite regulation and satiety signalling
• Demonstrates involvement in glucose metabolism and insulin response pathways
• Investigated for effects on body weight regulation and energy balance
• Shows potential influence on cardiovascular and metabolic risk markers
• Exhibits sustained GLP-1 receptor activity in controlled research models
Semaglutide is widely researched for its ability to influence multiple metabolic and endocrine pathways simultaneously, making it a compound of significant interest in laboratory environments focused on metabolic health, weight regulation mechanisms, and endocrine signalling research.
For research purposes only.
Not approved for human consumption.
Supporting Research
Appetite regulation and body weight signalling
Wilding et al., New England Journal of Medicine – Demonstrated significant effects on appetite control and body weight regulation via GLP-1 receptor pathways in controlled trials
https://pubmed.ncbi.nlm.nih.gov/33567185/
Glucose metabolism and insulin signalling
Marso et al., New England Journal of Medicine – Identified improved glycaemic control and sustained metabolic effects through GLP-1 receptor activation
https://pubmed.ncbi.nlm.nih.gov/27633186/
Cardiometabolic and systemic effects
Nauck et al., Diabetes, Obesity and Metabolism – Reviewed systemic metabolic effects, receptor selectivity, and long-acting peptide behaviour in research models
https://pubmed.ncbi.nlm.nih.gov/30370641/
